Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AXO-AAV-GM2
- Development stage
- Discontinued
- Lead developer
- Sio Gene Therapies
- Modality
- Gene Therapies, Recombinant Proteins and Enzymes
- Administration
- Intrathecal, Intracerebroventricular
01
Overview
AXO-AAV-GM2 is an investigational gene therapy designed to treat GM2 gangliosidosis, which includes Tay-Sachs disease and Sandhoff disease. These are rare, fatal pediatric neurodegenerative disorders caused by mutations in the HEXA (Tay-Sachs) or HEXB (Sandhoff) genes, leading to deficiency of the β-hexosaminidase A enzyme. AXO-AAV-GM2 delivers functional copies of both the HEXA and HEXB genes using two co-administered adeno-associated virus serotype rh8 (AAVrh8) vectors directly into the central nervous system. This approach aims to restore HexA enzyme activity, slow or halt neurodegeneration, and potentially improve clinical outcomes for affected children. The therapy has received Orphan Drug and Rare Pediatric Disease Designation from the FDA and is currently being evaluated in phase 1/2 clinical trials[1][3][5][7].
- Other names
- AAVrh8-HEXA/HEXBrecombinant adeno-associated virus vector encoding human HEXA and HEXB
02
Targets
HEXA (Hexosaminidase subunit alpha)HEXB (Beta-hexosaminidase subunit beta)
Beyond the preview
Go deeper on AXO-AAV-GM2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AXO-AAV-GM2.